Chimeric virus-like particles containing a conserved region of the G protein in combination with a single peptide of the M2 protein confer protection against respiratory syncytial virus infection

Antiviral Research

Volumn 131, Issue , 2016, Pages 131-140

  Qiao, Lei ^a   Zhang, Yuan ^a   Chai, Feng ^a   Tan, Yiluo ^a   Huo, Chunling ^a   Pan, Zishu ^a  

^a WUHAN UNIVERSITY   (China)

Author keywords

Hepatitis B virus core protein (HBc); Lung pathology; Respiratory syncytial virus (RSV); RSV attachment glyco (G) protein; Subunit vaccine; Virus like particle (VLP)

Indexed keywords

CHIMERIC PROTEIN; GAMMA INTERFERON; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; PROTEIN M2; RESPIRATORY SYNCYTIAL VIRUS VACCINE; TUMOR NECROSIS FACTOR ALPHA; VIRUS GLYCOPROTEIN; VIRUS LIKE PARTICLE VACCINE; CYTOKINE; EPITOPE; G GLYCOPROTEIN, RESPIRATORY SYNCYTIAL VIRUS; HEPATITIS B CORE ANTIGEN; IMMUNOGLOBULIN G; MATRIX PROTEIN; NEUTRALIZING ANTIBODY; SUBUNIT VACCINE; VIRUS ANTIBODY; VIRUS FUSION PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; FEMALE; HUMORAL IMMUNITY; IN VITRO STUDY; LUNG HOMOGENATE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL VIRUS INFECTION; VACCINATION; VIRAL CLEARANCE; VIRUS LIKE AGENT; VIRUS LOAD; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; BLOOD; CELL LINE; GENETICS; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNOLOGY; LUNG; PATHOLOGY; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; VIROLOGY;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CELL LINE; CYTOKINES; EPITOPES; HEPATITIS B CORE ANTIGENS; IMMUNOGLOBULIN G; LUNG; MICE; MICE, INBRED BALB C; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; VACCINES, SUBUNIT; VACCINES, VIRUS-LIKE PARTICLE; VIRAL FUSION PROTEINS; VIRAL MATRIX PROTEINS;

EID: 84968903314     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2016.05.001     Document Type: Article

References (81)

1. I.M. Belyakov, and J.D. Ahlers What role does the route of immunization play in the generation of protective immunity against mucosal pathogens? J. Immunol. 183 2009 6883 6892
2. W. Bohm, T. Mertens, R. Schirmbeck, and J. Reimann Routes of plasmid DNA vaccination that prime murine humoral and cellular immune responses Vaccine 16 1998 949 954
3. M.S. Boukhvalova, G.A. Prince, L. Soroush, D.C. Harrigan, S.N. Vogel, and J.C. Blanco The TLR4 agonist, monophosphoryl lipid A, attenuates the cytokine storm associated with respiratory syncytial virus vaccine-enhanced disease Vaccine 24 2006 5027 5035
4. C. Breese, G.A. Weinberg, A.K. Blumkin, K.M. Edwards, M.A. Staat, A.F. Schultz, K.A. Poehling, P.G. Szilagyi, M.R. Griffin, J.V. Williams, Y.W. Zhu, C.G. Grijalva, M.M. Prill, and M.K. Iwane Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age Pediatrics 132 2013 E341 E348
5. P.A. Cane, D.A. Matthews, and C.R. Pringle Identification of variable domains of the attachment (g)protein of subgroup-a respiratory syncytial viruses J. Gen. Virol. 72 1991 2091 2096
6. J. Chin, R.L. Magoffin, L.A. Shearer, J.H. Schieble, and E.H. Lennette Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population Am. J. Epidemiol. 89 1969 449 463
7. M. Connors, N.A. Giese, A.B. Kulkarni, C.Y. Firestone, H.C. Morse, and B.R. Murphy Enhanced pulmonary histopathology induced by respiratory syncytial virus (rsv) challenge of formalin-inactivated rsv-immunized balb/c mice is abrogated by depletion of interleukin-4 (Il-4) and Il-10 J. Virol. 68 1994 5321 5325
8. M. Connors, A.B. Kulkarni, C.Y. Firestone, K.L. Holmes, H.C. Morse, A.V. Sotnikov, and B.R. Murphy Pulmonary histopathology induced by respiratory syncytial virus (rsv) challenge of formalin-inactivated rsv-immunized balb/c mice is abrogated by depletion of Cd4+ T-cells J. Virol. 66 1992 7444 7451
9. J.E. Crowe Jr.; P.T. Bui, G.R. Siber, W.R. Elkins, R.M. Chanock, and B.R. Murphy Cold-passaged, temperature-sensitive mutants of human respiratory syncytial virus (RSV) are highly attenuated, immunogenic, and protective in seronegative chimpanzees, even when RSV antibodies are infused shortly before immunization Vaccine 13 1995 847 855
10. R.A. Crowther, N.A. Kiselev, B. Böttcher, J.A. Berriman, J.A. Borisova, V. Ose, and P. Pumpens Three-dimensional structure of hepatitis B virus core particles determined by electron cryomicroscopy Cell 77 1994 943 950
11. A.R. Falsey, P.A. Hennessey, M.A. Formica, C. Cox, and E.E. Walsh Respiratory syncytial virus infection in elderly and high-risk adults N. Engl. J. Med. 352 2005 1749 1759
12. O. Garcia, M. Martin, J. Dopazo, J. Arbiza, S. Frabasile, J. Russi, M. Hortal, P. Perezbrena, I. Martinez, B. Garciabarreno, and J.A. Melero Evolutionary pattern of human respiratory syncytial virus (subgroup a): cocirculating lineages and correlation of genetic and antigenic changes in the G glycoprotein J. Virology 68 1994 5448 5459
13. B.S. Graham Biological challenges and technological opportunities for respiratory syncytial virus vaccine development Immunol. Rev. 239 2011 149 166
14. W. Gut, K. Pancer, E. Abramczuk, A. Czescik, M. Dunal-Szczepaniak, B. Lipka, and B. Litwinska RSV respiratory infection in children under 5 y.o.-dynamics of the immune response Th1/Th2 and IgE Przeglad Epidemiol. 67 2013 17 22 105-109
15. G.E. Hancock, D.J. Speelman, K. Heers, E. Bortell, J. Smith, and C. Cosco Generation of atypical pulmonary inflammatory responses in BALB/c mice after immunization with the native attachment (G) glycoprotein of respiratory syncytial virus J. Virol. 70 1996 7783 7791
16. M.L. Houben, F.E. Coenjaerts, J.W. Rossen, M.E. Belderbos, R.W. Hofland, J.L. Kimpen, and L. Bont Disease severity and viral load are correlated in infants with primary respiratory syncytial virus infection in the community J. Med. Virol. 82 2010 1266 1271
17. T.S. Howard, L.H. Hoffman, P.E. Stang, and E.A. Simoes Respiratory syncytial virus pneumonia in the hospital setting: length of stay, charges, and mortality J. Pediatr. 137 2000 227 232
18. S.C. Hsu, D. Chargelegue, and M.W. Steward Reduction of respiratory syncytial virus titer in the lungs of mice after intranasal immunization with a chimeric peptide consisting of a single CTL epitope linked to a fusion peptide Virology 240 1998 376 381
19. H.S. Hwang, Y.M. Kwon, J.S. Lee, S.E. Yoo, Y.N. Lee, E.J. Ko, M.C. Kim, M.K. Cho, Y.T. Lee, Y.J. Jung, J.Y. Lee, J.D. Li, and S.M. Kang Co-immunization with virus-like particle and DNA vaccines induces protection against respiratory syncytial virus infection and bronchiolitis Antivir. Res. 110 2014 115 123
20. M. Iqbal, W. Lin, I. Jabbal-Gill, S.S. Davis, M.W. Steward, and L. Illum Nasal delivery of chitosan-DNA plasmid expressing epitopes of respiratory syncytial virus (RSV) induces protective CTL responses in BALB/c mice Vaccine 21 2003 1478 1485
21. T.R. Johnson, J.E. Johnson, S.R. Roberts, G.W. Wertz, R.A. Parker, and B.S. Graham Priming with secreted glycoprotein G of respiratory syncytial virus (RSV) augments interleukin-5 production and tissue eosinophilia after RSV challenge J. Virol. 72 1998 2871 2880
22. T.R. Johnson, R.A. Parker, J.E. Johnson, and B.S. Graham IL-13 is sufficient for respiratory syncytial virus G glycoprotein-induced eosinophilia after respiratory syncytial virus challenge J. Immunol. 170 2003 2037 2045
23. T.R. Johnson, S. Rao, R.A. Seder, M. Chen, and B.S. Graham TLR9 agonist, but not TLR7/8, functions as an adjuvant to diminish FI-RSV vaccine-enhanced disease, while either agonist used as therapy during primary RSV infection increases disease severity Vaccine 27 2009 3045 3052
24. T.R. Johnson, M.E. Rothenberg, and B.S. Graham Pulmonary eosinophilia requires interleukin-5, eotaxin-1, and CD4+ T cells in mice immunized with respiratory syncytial virus G glycoprotein J. Leukoc. Biol. 84 2008 748 759
25. A.Z. Kapikian, R.H. Mitchell, R.M. Chanock, R.A. Shvedoff, and C.E. Stewart An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine Am. J. Epidemiol. 89 1969 405 421
26. H.W. Kim, S.L. Leikin, J. Arrobio, C.D. Brandt, R.M. Chanock, and R.H. Parrott Cell-mediated immunity to respiratory syncytial virus induced by inactivated vaccine or by infection Pediatr. Res. 10 1976 75 78
27. K.H. Kim, Y.T. Lee, H.S. Hwang, Y.M. Kwon, M.C. Kim, E.J. Ko, J.S. Lee, Y. Lee, and S.M. Kang Virus-like particle vaccine containing the f protein of respiratory syncytial virus confers protection without pulmonary disease by modulating specific subsets of dendritic cells and effector T cells J. Virol. 89 2015 11692 11705
28. C.J. Knudson, S.M. Hartwig, D.K. Meyerholz, and S.M. Varga RSV vaccine-enhanced disease is orchestrated by the combined actions of distinct CD4 T cell subsets PLoS Pathog. 11 2015 e1004757
29. P.A. Kratz, B. Bottcher, and M. Nassal Native display of complete foreign protein domains on the surface of hepatitis B virus capsids Proc. Natl. Acad. Sci. U.S.A. 96 1999 1915 1920
30. A.B. Kulkarni, P.L. Collins, I. Bacik, J.W. Yewdell, J.R. Bennink, J.E. Crowe Jr.; and B.R. Murphy Cytotoxic T cells specific for a single peptide on the M2 protein of respiratory syncytial virus are the sole mediators of resistance induced by immunization with M2 encoded by a recombinant vaccinia virus J. Virol. 69 1995 1261 1264
31. A.B. Kulkarni, M. Connors, C.Y. Firestone, H.C. Morse 3rd, and B.R. Murphy The cytolytic activity of pulmonary CD8+ lymphocytes, induced by infection with a vaccinia virus recombinant expressing the M2 protein of respiratory syncytial virus (RSV), correlates with resistance to RSV infection in mice J. Virol. 67 1993 1044 1049
32. S. Lee, F.S. Quan, Y. Kwon, K. Sakamoto, S.M. Kang, R.W. Compans, and M.L. Moore Additive protection induced by mixed virus-like particles presenting respiratory syncytial virus fusion or attachment glycoproteins Antivir. Res. 111 2014 129 135
33. S. Lee, K.L. Stokes, M.G. Currier, K. Sakamoto, N.W. Lukacs, E. Celis, and M.L. Moore Vaccine-elicited CD8+ T cells protect against respiratory syncytial virus strain A2-line19F-induced pathogenesis in BALB/c mice J. Virol. 86 2012 13016 13024
34. X. Li, S. Sambhara, C.X. Li, L. Ettorre, I. Switzer, G. Cates, O. James, M. Parrington, R. Oomen, R.P. Du, and M. Klein Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate Virology 269 2000 54 65
35. L.W. McGinnes, K.A. Gravel, R.W. Finberg, E.A. Kurt-Jones, M.J. Massare, G. Smith, M.R. Schmidt, and T.G. Morrison Assembly and immunological properties of Newcastle disease virus-like particles containing the respiratory syncytial virus F and G proteins J. Virol. 85 2011 366 377
36. H. Mok, S. Lee, T.J. Utley, B.E. Shepherd, V.V. Polosukhin, M.L. Collier, N.L. Davis, R.E. Johnston, and J.E. Crowe Jr. Venezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats J. Virol. 81 2007 13710 13722
37. S. Mukhopadhyay, J.R. Hoidal, and T.K. Mukherjee Role of TNFalpha in pulmonary pathophysiology Respir. Res. 7 2006 125
38. M.R. Murawski, L.W. McGinnes, R.W. Finberg, E.A. Kurt-Jones, M.J. Massare, G. Smith, P.M. Heaton, A.E. Fraire, and T.G. Morrison Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice, with no evidence of immunopathology J. Virol. 84 2010 1110 1123
39. B.R. Murphy, G.A. Prince, E.E. Walsh, H.W. Kim, R.H. Parrott, V.G. Hemming, W.J. Rodriguez, and R.M. Chanock Dissociation between serum neutralizing and glycoprotein antibody-responses of infants and children who received inactivated respiratory syncytial virus-Vaccine J. Clin. Microbiol. 24 1986 197 202
40. B.R. Murphy, and E.E. Walsh Formalin-inactivated respiratory syncytial virus-vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity J. Clin. Microbiol. 26 1988 1595 1597
41. H. Nair, D.J. Nokes, B.D. Gessner, M. Dherani, S.A. Madhi, R.J. Singleton, K.L. O'Brien, A. Roca, P.F. Wright, N. Bruce, A. Chandran, E. Theodoratou, A. Sutanto, E.R. Sedyaningsih, M. Ngama, P.K. Munywoki, C. Kartasasmita, E.A. Simoes, I. Rudan, M.W. Weber, and H. Campbell Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis Lancet 375 2010 1545 1555
42. M. Nassal, C. Skamel, P.A. Kratz, R. Wallich, T. Stehle, and M.M. Simon A fusion product of the complete Borrelia burgdorferi outer surface protein A (OspA) and the hepatitis B virus capsid protein is highly immunogenic and induces protective immunity similar to that seen with an effective lipidated OspA vaccine formula Eur. J. Immunol. 35 2005 655 665
43. M. Nassal, C. Skamel, M. Vogel, P.A. Kratz, T. Stehle, R. Wallich, and M.M. Simon Development of hepatitis B virus capsids into a whole-chain protein antigen display platform: new particulate lyme disease vaccines Int. J. Med. Microbiol. 298 2008 135 142
44. T.N. Nguyen, U.F. Power, A. Robert, J.F. Haeuw, K. Helffer, A. Perez, M.A. Asin, N. Corvaia, and C. Libon The respiratory syncytial virus G protein conserved domain induces a persistent and protective antibody response in rodents PLoS One 7 2012 e34331
45. M.R. Olson, S.M. Hartwig, and S.M. Varga The number of respiratory syncytial virus (RSV)-specific memory CD8 T cells in the lung to inhibit rsv vaccine-enhanced is critical for their ability pulmonary eosinophilia J. Immunol. 181 2008 7958 7968
46. P.J. Openshaw, and J.S. Tregoning Immune responses and disease enhancement during respiratory syncytial virus infection Clin. Microbiol. Rev. 18 2005 541 555
47. R.S. Peebles Jr.; and B.S. Graham Pathogenesis of respiratory syncytial virus infection in the murine model Proc. Am. Thorac. Soc. 2 2005 110 115
48. P.A. Piedra, S.G. Cron, A. Jewell, N. Hamblett, R. McBride, M.A. Palacio, R. Ginsberg, C.M. Oermann, P.W. Hiatt, and G. Purified Fusion Protein Vaccine Study Immunogenicity of a new purified fusion protein vaccine to respiratory syncytial virus: a multi-center trial in children with cystic fibrosis Vaccine 21 2003 2448 2460
49. E.M. Plummer, and M. Manchester Viral nanoparticles and virus-like particles: platforms for contemporary vaccine design Wires Nanomed. Nanobi 3 2011 174 196
50. U.F. Power, H. Plotnicky-Gilquin, L. Goetsch, T. Champion, A. Beck, J.F. Haeuw, T.N. Nguyen, J.Y. Bonnefoy, and N. Corvaia Identification and characterisation of multiple linear B cell protectopes in the respiratory syncytial virus G protein Vaccine 19 2001 2345 2351
51. F.S. Quan, Y. Kim, S. Lee, H. Yi, S.M. Kang, J. Bozja, M.L. Moore, and R.W. Compans Viruslike particle vaccine induces protection against respiratory syncytial virus infection in mice J.Infect. Dis. 204 2011 987 995
52. F.S. Quan, Y. Kim, S. Lee, H. Yi, S.M. Kang, J. Bozja, M.L. Moore, and R.W. Compans Viruslike particle vaccine induces protection against respiratory syncytial virus infection in mice J. Infect. Dis. 205 2012 520 521
53. K. Roose, S. De Baets, B. Schepens, and X. Saelens Hepatitis B core-based virus-like particles to present heterologous epitopes Expert Rev. Vaccines 12 2013 183 198
54. + T cell immunity against human respiratory syncytial virus Vaccine 32 2014 6130 6137
55. J.A. Rutigliano, and B.S. Graham Prolonged production of TNF-alpha exacerbates illness during respiratory syncytial virus infection J. Immunol. 173 2004 3408 3417
56. H.Y. Shao, S.L. Yu, C. Sia, Y. Chen, E. Chitra, I.H. Chen, N. Venkatesan, C.H. Leng, P. Chong, and Y.H. Chow Immunogenic properties of RSV-B1 fusion (F) protein gene-encoding recombinant adenoviruses Vaccine 27 2009 5460 5471
57. C.P. Simmons, T. Hussell, T. Sparer, G. Walzl, P. Openshaw, and G. Dougan Mucosal delivery of a respiratory syncytial virus CTL peptide with enterotoxin-based adjuvants elicits protective, immunopathogenic, and immunoregulatory antiviral CD8(+) T cell responses J. Immunol. 166 2001 1106 1113
58. S.R. Singh, V.A. Dennis, C.L. Carter, S.R. Pillai, A. Jefferson, S.V. Sahi, and E.G. Moore Immunogenicity and efficacy of recombinant RSV-F vaccine in a mouse model Vaccine 25 2007 6211 6223
59. C. Skamel, M. Ploss, B. Bottcher, T. Stehle, R. Wallich, M.M. Simon, and M. Nassal Hepatitis B virus capsid-like particles can display the complete, dimeric outer surface protein C and stimulate production of protective antibody responses against Borrelia burgdorferi infection J. Biol. Chem. 281 2006 17474 17481
60. T.E. Sparer, S. Matthews, T. Hussell, A.J. Rae, B. Garcia-Barreno, J.A. Melero, and P.J.M. Openshaw Eliminating a region of respiratory syncytial virus attachment protein allows induction of protective immunity without vaccine-enhanced lung eosinophilia J. Exp. Med. 187 1998 1921 1926
61. + T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection J. Exp. Med. 186 1997 421 432
62. A. Srikiatkhachorn, and T.J. Braciale Virus-specific memory and effector T lymphocytes exhibit different cytokine responses to antigens during experimental murine respiratory syncytial virus infection J. Virol. 71 1997 678 685
63. A. Srikiatkhachorn, W. Chang, and T.J. Braciale Induction of Th-1 and Th-2 responses by respiratory syncytial virus attachment glycoprotein is epitope and major histocompatibility complex independent J. Virol. 73 1999 6590 6597
64. K.L. Stokes, M.H. Chi, K. Sakamoto, D.C. Newcomb, M.G. Currier, M.M. Huckabee, S. Lee, K. Goleniewska, C. Pretto, J.V. Williams, A. Hotard, T.P. Sherrill, R.S. Peebles Jr.; and M.L. Moore Differential pathogenesis of respiratory syncytial virus clinical isolates in BALB/c mice J. Virol. 85 2011 5782 5793
65. T. Suda, M. Kawano, Y. Nogi, N. Ohno, T. Akatsuka, and M. Matsui The route of immunization with adenoviral vaccine influences the recruitment of cytotoxic T lymphocytes in the lung that provide potent protection from influenza A virus Antivir. Res. 91 2011 252 258
66. W.M. Sullender, M.A. Mufson, L.J. Anderson, and G.W. Wertz Genetic diversity of the attachment protein of subgroup-b respiratory syncytial viruses J. Virol. 65 1991 5425 5434
67. T. Takimoto, J.L. Hurwitz, C. Coleclough, C. Prouser, S. Krishnamurthy, X. Zhan, K. Boyd, R.A. Scroggs, B. Brown, Y. Nagai, A. Portner, and K.S. Slobod Recombinant Sendai virus expressing the G glycoprotein of respiratory syncytial virus (RSV) elicits immune protection against RSV J. Virol. 78 2004 6043 6047
68. R.S. Tang, R.R. Spaete, M.W. Thompson, M. MacPhail, J.M. Guzzetta, P.C. Ryan, K. Reisinger, P. Chandler, M. Hilty, R.E. Walker, M.M. Gomez, and G.A. Losonsky Development of a PIV-vectored RSV vaccine: preclinical evaluation of safety, toxicity, and enhanced disease and initial clinical testing in healthy adults Vaccine 26 2008 6373 6382
69. P. Tao, M. Luo, R. Pan, D. Ling, S. Zhou, P. Tien, and Z. Pan Enhanced protective immunity against H5N1 influenza virus challenge by vaccination with DNA expressing a chimeric hemagglutinin in combination with an MHC class I-restricted epitope of nucleoprotein in mice Antivir. Res. 81 2009 253 260
70. P.W. Tebbey, M. Hagen, and G.E. Hancock Atypical pulmonary eosinophilia is mediated by a specific amino acid sequence of the attachment (G) protein of respiratory syncytial virus J. Exp. Med. 188 1998 1967 1972
71. N. Ternette, B. Tippler, K. Uberla, and T. Grunwald Immunogenicity and efficacy of codon optimized DNA vaccines encoding the F-protein of respiratory syncytial virus Vaccine 25 2007 7271 7279
72. S.M. Varga, X.T. Wang, R.M. Welsh, and T.J. Braciale Immunopathology in RSV infection is mediated by a discrete oligoclonal subset of antigen-specific CD4(+) T cells Immunity 15 2001 637 646
73. S.M. Varga, E.L. Wissinger, and T.J. Braciale The attachment (G) glycoprotein of respiratory syncytial virus contains a single immunodominant epitope that elicits both Th1 and Th2CD4(+) T cell responses J. Immunol. 165 2000 6487 6495
74. P. Walpita, L.M. Johns, R. Tandon, and M.L. Moore Mammalian cell-derived respiratory syncytial virus-like particles protect the lower as well as the upper respiratory tract Plos One 2015 10
75. E.E. Walsh, D.R. Peterson, and A.R. Falsey Risk factors for severe respiratory syncytial virus infection in elderly persons J. Infect. Dis 189 2004 233 238
76. X.J. Wang, K. Gu, Q.Y. Xiong, L. Shen, R.Y. Cao, M.H. Li, T.M. Li, J. Wu, and J.J. Liu A novel virus-like particle based on hepatitis B core antigen and substrate-binding domain of bacterial molecular chaperone DnaK Vaccine 27 2009 7377 7384
77. Z. Wang, B.Y. Chua, J.V. Ramos, S.M. Parra, E. Fairmaid, L.E. Brown, D.C. Jackson, and K. Kedzierska Establishment of functional influenza virus-specific CD8(+) T cell memory pools after intramuscular immunization Vaccine 33 2015 5148 5154
78. D.L. Woodland, and J.E. Kohlmeier Migration, maintenance and recall of memory T cells in peripheral tissues Nat. Rev. Immunol. 9 2009 153 161
79. X. Zhan, J.L. Hurwitz, S. Krishnamurthy, T. Takimoto, K. Boyd, R.A. Scroggs, S. Surman, A. Portner, and K.S. Slobod Respiratory syncytial virus (RSV) fusion protein expressed by recombinant Sendai virus elicits B-cell and T-cell responses in cotton rats and confers protection against RSV subtypes A and B Vaccine 25 2007 8782 8793
80. W. Zhang, Y. Choi, L.M. Haynes, J.L. Harcourt, L.J. Anderson, L.P. Jones, and R.A. Tripp Vaccination to induce antibodies blocking the CX3C-CX3CR1 interaction of respiratory syncytial virus G protein reduces pulmonary inflammation and virus replication in mice J. Virol. 84 2010 1148 1157
81. Y. Zhang, L. Qiao, X. Hu, K. Zhao, Y. Zhang, F. Chai, and Z. Pan Baculovirus vectors expressing F proteins in combination with virus-induced signaling adaptor (VISA) molecules confer protection against respiratory syncytial virus infection Vaccine 34 2016 252 260